Cannabis use disorder

Last updated

Cannabis use disorder
Other namesCannabis addictions, marijuana addiction
Reduced blood flow in cannabis users.jpg
Reduced blood flow in prefrontal cortex of adolescent cannabis users [1]
Specialty Psychiatry
Symptoms Dependency of THC and withdrawal signs such as dysphoria (anxiety, irritability, depression, depersonalization, restlessness), disturbed sleep, gastrointestinal problems, and decreased appetite
Usual onsetPotential progression to additional substance use disorders
Risk factors Adolescence and high-frequency use
Treatment Psychotherapy
Medication None approved, experimental only

Cannabis use disorder (CUD), also known as cannabis addiction or marijuana addiction, is a psychiatric disorder defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and ICD-10 as the continued use of cannabis despite clinically significant impairment. [2] [3]

Contents

There is a common misconception that cannabis use disorder does not exist. [4] [5]

Signs and symptoms

Cannabis use is sometimes comorbid for other mental health problems, such as mood and anxiety disorders, and discontinuing cannabis use is difficult for some users. [6] Psychiatric comorbidities are often present in dependent cannabis users including a range of personality disorders. [7]

Based on annual survey data, some high school seniors who report smoking daily (nearly 7%, according to one study) may function at a lower rate in school than students that do not. [8] The sedating and anxiolytic properties of tetrahydrocannabinol (THC) in some users might make the use of cannabis an attempt to self-medicate personality or psychiatric disorders. [9]

Dependency

Prolonged cannabis use produces both pharmacokinetic changes (how the drug is absorbed, distributed, metabolized, and excreted) and pharmacodynamic changes (how the drug interacts with target cells) to the body. These changes require the user to consume higher doses of the drug to achieve a common desirable effect (known as a higher tolerance), reinforcing the body's metabolic systems for eliminating the drug more efficiently and further down-regulating cannabinoid receptors in the brain. [10]

Cannabis users have shown decreased reactivity to dopamine, suggesting a possible link to a dampening of the reward system of the brain and an increase in negative emotion and addiction severity. [11]

Cannabis users can develop tolerance to the effects of THC. Tolerance to the behavioral and psychological effects of THC has been demonstrated in adolescent humans and animals. [12] [13] The mechanisms that create this tolerance to THC are thought to involve changes in cannabinoid receptor function. [12]

One study has shown that between 2001–2002 and 2012–2013, the use of marijuana in the US doubled. [14]

Cannabis dependence develops in about 9% of users, significantly less than that of heroin, cocaine, alcohol, and prescribed anxiolytics, [15] but slightly higher than that for psilocybin, mescaline, or LSD. [16] Of those who use cannabis daily, 10–20% develop dependence. [17]

Withdrawal

Cannabis withdrawal symptoms occur in half of people being treated for cannabis use disorders. [18] Symptoms may include dysphoria, anxiety, irritability, depression, restlessness, disturbed sleep, gastrointestinal symptoms, and decreased appetite. It is often paired with rhythmic movement disorder. Most symptoms begin during the first week of abstinence and resolve after a few weeks. [6] About 12% of heavy cannabis users showed cannabis withdrawal as defined by the DSM-5, and this was associated with significant disability as well as mood, anxiety and personality disorders. [19] Furthermore, a study on 49 dependent cannabis users over a two week period of abstinence proved most prominently symptoms of nightmares (although lacking distress in subjects) and anger issues (causing distress). [20]

Cause

Cannabis addiction is often due to prolonged and increasing use of the drug. Increasing the strength of the cannabis taken and increasing use of more effective methods of delivery often increase the progression of cannabis dependency. Approximately 17.0% of weekly and 19.0% of daily cannabis smokers can be classified as cannabis dependent. [21] In addition to cannabis use, it has been shown that co-use of cannabis and tobacco can result in an elevated risk of cannabis use disorder. [22] It can also be caused by being prone to becoming addicted to substances, which can be genetically or environmentally acquired. [23]

Risk factors

Certain factors are considered to heighten the risk of developing cannabis dependence. Longitudinal studies over a number of years have enabled researchers to track aspects of social and psychological development concurrently with cannabis use. Increasing evidence is being shown for the elevation of associated problems by the frequency and age at which cannabis is used, with young and frequent users being at most risk. [24] The frequency of cannabis use and duration of use are considered to be major risk factors for development of cannabis use disorder. The strength of cannabis used, with higher THC content conferring a heightened risk, is also thought to be a risk factor. [25] Concomitant alcohol or tobacco use, a history of adverse childhood experiences, depression or other psychiatric disorders, stressful life events and parental cannabis use may also increase the risk of developing cannabis use disorder. [25]

The main factors in Australia, for example, related to a heightened risk for developing problems with cannabis use include frequent use at a young age; personal maladjustment; emotional distress; poor parenting; school drop-out; affiliation with drug-using peers; moving away from home at an early age; daily cigarette smoking; and ready access to cannabis. The researchers concluded there is emerging evidence that positive experiences to early cannabis use are a significant predictor of late dependence and that genetic predisposition plays a role in the development of problematic use. [26]

High risk groups

A number of groups have been identified as being at greater risk of developing cannabis dependence and, in Australia have been found to include adolescent populations, Aboriginal and Torres Strait Islanders and people with mental health conditions. [27]

Adolescents

The endocannabinoid system is directly involved in adolescent brain development. [28] Adolescent cannabis users are therefore particularly vulnerable to the potential adverse effects of cannabis use. [28] Adolescent cannabis use is associated with increased cannabis misuse as an adult, issues with memory and concentration, long-term cognitive complications, and poor psychiatric outcomes including social anxiety, suicidality and addiction. [29] [30] [31]

There are several reasons why adolescents start a smoking habit. According to a study completed by Bill Sanders, influence from friends, difficult household problems, and experimentation are some of the reasons why this population starts to smoke cannabis. [32] This segment of population seems to be one of the most influenceable group there is. [33] They want to follow the group and look "cool", "hip" and accepted by their friends. [32] This fear of rejection plays a big role in their decision to use cannabis. However it does not seem to be the most important factor. According to a study from Canada, the lack of knowledge about cannabis seems to be the main reason why adolescents start to smoke. [34] The authors observed a high correlation between adolescents that knew about the mental and physical harms of cannabis and their consumption. [34] Of the 1045 young participants in the study, those who could name the least number of negative effects about this drug were usually the ones who were consuming it. [34] They were not isolated cases either. Actually, the study showed that the proportion of teenagers who saw cannabis as a high-risk drug and the ones who thought the contrary was about the same. [35]

Pregnancy

The American College of Obstetricians and Gynecologists advise against cannabis use during pregnancy or lactation. [36] There is an association between smoking cannabis during pregnancy and low birth weight. [37] Smoking cannabis during pregnancy can lower the amount of oxygen delivered to the developing fetus, which can restrict fetal growth. [37] The active ingredient in cannabis (Δ9-tetrahydrocannabinol, THC) is fat soluble and can enter into breastmilk during lactation. [37] THC in breastmilk can then subsequently be taken up by a breastfeeding infant, as shown by the presence of THC in the infant's feces. However, the evidence for long-term effects of exposure to THC through breastmilk is unclear. [38] [39] [40]

Diagnosis

Cannabis use disorder is recognized in the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), [41] which also added cannabis withdrawal as a new condition. [42] In the 2013 revision for the DSM-5, DSM-IV abuse and dependence were combined into cannabis use disorder. The legal problems criterion (from cannabis abuse) has been removed, and the craving criterion was newly added, resulting in a total of eleven criteria: hazardous use, social/interpersonal problems, neglected major roles, withdrawal, tolerance, used larger amounts/longer, repeated attempts to quit/control use, much time spent using, physical/psychological problems related to use, activities given up and craving. For a diagnosis of DSM-5 cannabis use disorder, at least two of these criteria need to be present in the last twelve-month period. Additionally, three severity levels have been defined: mild (two or three criteria), moderate (four or five criteria) and severe (six or more criteria) cannabis use disorder. [43]

Cannabis use disorder is also recognized in the eleventh revision of the International Classification of Diseases (ICD-11), [44] adding more subdivisions including time intervals of pattern of use (episodic, continuous, or unspecified) and dependence (current, early full remission, sustained partial remission, sustained full remission, or unspecified) compared to the 10th revision. [45]

A 2019 meta-analysis found that 34% of people with cannabis-induced psychosis transitioned to schizophrenia. This was found to be comparatively higher than hallucinogens (26%) and amphetamines (22%). [46]

To screen for cannabis-related problems, several methods are used. Scales specific to cannabis, which provides the benefit of being cost efficient compared to extensive diagnostic interviews, include the Cannabis Abuse Screening Test (CAST), Cannabis Use Identification Test (CUDIT), and Cannabis Use Problems Identification Test (CUPIT). [47] Scales for general drug use disorders are also used, including the Severity Dependence Scale (SDS), Drug Use Disorder Identification Test (DUDIT), and Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). [48] However, there are no gold standard and both older and newer scales are still in use. [48] To quantify cannabis use, methods such as Timeline Follow-Back (TLFB) and Cannabis Use Daily (CUD) are used. [48] These methods measure general consumption and not grams of psychoactive substance as the concentration of THC may vary among drug users. [48]

Treatment

Clinicians differentiate between casual users who have difficulty with drug screens, and daily heavy users, to a chronic user who uses multiple times a day. [9] In the US, as of 2013, cannabis is the most commonly identified illicit substance used by people admitted to treatment facilities. [17] Demand for treatment for cannabis use disorder increased internationally between 1995 and 2002. [49] In the United States, the average adult who seeks treatment has consumed cannabis for over 10 years almost daily and has attempted to quit six or more times. [16]

Treatment options for cannabis dependence are far fewer than for opiate or alcohol dependence. Most treatment falls into the categories of psychological or psychotherapeutic, intervention, pharmacological intervention or treatment through peer support and environmental approaches. [26] No medications have been found effective for cannabis dependence, [50] but psychotherapeutic models hold promise. [6] Screening and brief intervention sessions can be given in a variety of settings, particularly at doctor's offices, which is of importance as most cannabis users seeking help will do so from their general practitioner rather than a drug treatment service agency. [51]

The most commonly accessed forms of treatment in Australia are 12-step programmes, physicians, rehabilitation programmes, and detox services, with inpatient and outpatient services equally accessed. [52] In the EU approximately 20% of all primary admissions and 29% of all new drug clients in 2005, had primary cannabis problems. And in all countries that reported data between 1999 and 2005 the number of people seeking treatment for cannabis use increased. [53]

Psychological

Psychological intervention includes cognitive behavioral therapy (CBT), motivational enhancement therapy (MET), contingency management (CM), supportive-expressive psychotherapy (SEP), family and systems interventions, and twelve-step programs. [6] [54]

Evaluations of Marijuana Anonymous programs, modelled on the 12-step lines of Alcoholics Anonymous and Narcotics Anonymous, have shown small beneficial effects for general drug use reduction. [55] In 2006, the Wisconsin Initiative to Promote Healthy Lifestyles implemented a program that helps primary care physicians identify and address marijuana use problems in patients. [56]

Medication

As of 2023, there is no medication that has been proven effective for treating cannabis use disorder, research is focused on three treatment approaches: agonist substitution, antagonist, and modulation of other neurotransmitter systems. [6] [50] [25] More broadly, the goal of medication therapy for cannabis use disorder centers around targeting the stages of the addiction: acute intoxication/binge, withdrawal/negative affect, and preoccupation/anticipation. [57]

For the treatment of the withdrawal/negative affect symptom domain of cannabis use disorder, medications may work by alleviating restlessness, irritable or depressed mood, anxiety, and insomnia. [58] Bupropion, which is a norepinephrine–dopamine reuptake inhibitor, has been studied for the treatment of withdrawal with largely poor results. [58] Atomoxetine has also shown poor results, and is as a norepinephrine reuptake inhibitor, though it does increase the release of dopamine through downstream effects in the prefrontal cortex (an area of the brain responsible for planning complex tasks and behavior). [58] Venlafaxine, a serotonin–norepinephrine reuptake inhibitor, has also been studied for cannabis use disorder, with the thought that the serotonergic component may be useful for the depressed mood or anxious dimensions of the withdrawal symptom domain. [58] While venlafaxine has been shown to improve mood for people with cannabis use disorder, a clinical trial in this population actually found worse cannabis abstinence rates compared to placebo. [58] It is worth noting that venlafaxine is sometimes poorly tolerated, and infrequent use or abrupt discontinuation of its use can lead to withdrawal symptoms from the medication itself, including irritability, dysphoria, and insomnia. [59] It is possible that venlafaxine use actually exacerbated cannabis withdrawal symptoms, leading people to use more cannabis than placebo to alleviate their discomfort. [58] Mirtazapine, which increases serotonin and norepinephrine, has also failed to improve abstinence rates in people with cannabis use disorder. [58]

People sometimes use cannabis to cope with their anxiety, and cannabis withdrawal can lead to symptoms of anxiety. [58] Buspirone, a serotonin 1A receptor (5-HT1A) agonist, has shown limited efficacy for treating anxiety in people with cannabis use disorder, though there may be better efficacy in males than in females. [58] Fluoxetine, a selective serotonin reuptake inhibitor, has failed to show efficacy in adolescents with both cannabis use disorder and depression. [58] SSRIs are a class of antidepressant drugs that are also used for the treatment of anxiety disorders, such as generalized anxiety disorder. [60] Vilazodone, which has both SSRI and 5-HT1A agonism properties, also failed to increase abstinence rates in people with cannabis use disorder. [58]

Studies of divalproex have found no significant benefit, though some studies have found mixed results. [58] Baclofen, a GABAB receptor agonist and antispasmodic medication, has been found to reduce cravings but without a significant benefit towards preventing relapse or improving sleep. [58] Zolpidem, a GABAA receptor agonist and "Z-hypnotic" medication, has shown some efficacy in treating insomnia due to cannabis withdrawal, though there is a potential for misuse. [58] Entacapone was well tolerated and decreased cannabis cravings in a trial on a small number of patients. [6] Topiramate, an antiepileptic drug, has shown mixed results in adolescents, reducing the volume of cannabis consumption without significantly increasing abstinence, with somewhat poor tolerability. [58] Gabapentin, an indirect GABA modulator, has shown some preliminary benefit for reducing cravings and cannabis use. [58]

The agonist substitution approach is one that draws upon the analogy of the success of nicotine replacement therapy for nicotine addiction. Dronabinol, which is synthetic THC, has shown benefit in reducing cravings and other symptoms of withdrawal, though without preventing relapse or promoting abstinence. [58] Combination therapy with dronabinol and the α2-adrenergic receptor agonist lofexidine have shown mixed results, with possible benefits towards reducing withdrawal symptoms. [58] However, overall, the combination of dronabinol and lofexidine is likely not effective for the treatment of cannabis use disorder. [58] Nabilone, a synthetic THC analogue, has shown benefits in reducing symptoms of withdrawal such as difficulty sleeping, and decreased overall cannabis use. [58] Despite its psychoactive effects, the slower onset of action and longer duration of action of nabilone make it less likely to be abused than cannabis itself, which makes nabilone a promising harm reduction strategy for the treatment of cannabis use disorder. [58] The combination of nabilone and zolpidem has been shown to decrease sleep-related and mood-related symptoms of cannabis withdrawal, in addition to decreasing cannabis use. [58] Nabiximols, a combined THC and cannabidiol (CBD) product that is formulated as an oral (buccal) spray, has been shown to improve withdrawal symptoms without improving abstinence rates. [58] Oral CBD has not shown efficacy in reducing the signs or symptoms of cannabis use, and likely has no benefit in cannabis use withdrawal symptoms. [58] The CB1 receptor antagonist rimonabant has shown efficacy in reducing the effects of cannabis in users, but with a risk for serious psychiatric side effects. [58]

Naltrexone, a μ-opioid receptor antagonist, has shown mixed results for cannabis use disorder—both increasing the subjective effects of cannabis when given acutely, but potentially decreasing the overall use of cannabis with chronic administration. [58] N-acetylcysteine (NAC) has shown some limited benefit in decreasing cannabis use in adolescents, though not with adults. [58] Lithium, a mood stabilizer, has shown mixed results for treating symptoms of cannabis withdrawal, but is likely ineffective. [58] Quetiapine, a second-generation antipsychotic, has been shown to treat cannabis withdrawal related insomnia and decreased appetite at the expense of exacerbating cravings. [58] Oxytocin, a neuropeptide that the body produces, has shown some benefit in reducing the use of cannabis when administered intranasally in combination with motivational enhancement therapy sessions, though the treatment effect did not persist between sessions. [58]

CB1 antagonists such as rimonabant have been tested for utility in CUD. [61]

Barriers to treatment

Research that looks at barriers to cannabis treatment frequently cites a lack of interest in treatment, lack of motivation and knowledge of treatment facilities, an overall lack of facilities, costs associated with treatment, difficulty meeting program eligibility criteria and transport difficulties.[ dubious – discuss ] [62] [63] [64]

Epidemiology

According to the 2022 National Survey on Drug Use and Health, cannabis is one of the most widely used drugs in the world. [65] Research by the Pew Research Center from 2012 claims 42% of the US population have claimed to use cannabis at some point. [3] According to the 2019 National Survey on Drug Use and Health, 46% of U.S. adults say they have ever used marijuana. [66] An estimated 9% of those who use cannabis develop dependence. [16] [67] [ needs update ]

In the U.S., cannabis is the most commonly identified illicit substance used by people admitted to treatment facilities. [6] Most of these people were referred there by the criminal justice system. Of admittees 16% either went on their own, or were referred by family or friends. [68]

Of Australians aged 14 years and over 34.8% have used cannabis one or more times in their life. [69]

In the European Union (data as available in 2018, information for individual countries was collected between 2012 and 2017), 26.3% of adults aged 15–64 used cannabis at least once in their lives, and 7.2% used cannabis in the last year. The highest prevalence of cannabis use among 15 to 64 years old in the EU was reported in France, with 41.4% having used cannabis at least once in their life, and 2.17% used cannabis daily or almost daily. Among young adults (15–34 years old), 14.1% used cannabis in the last year. [70]

Among adolescents (15–16 years old) in a European school based study (ESPAD), 16% of students have used cannabis at least once in their life, and 7% (boys: 8%, girls: 5%) of students had used cannabis in the last 30 days. [71]

Globally, 22.1 million people (0.3% of the worlds population) were estimated to have cannabis dependence. [72]

Research

Medications such as SSRI antidepressants, mixed action antidepressants, bupropion, buspirone and atomoxetine may not be helpful to treat cannabis use disorder, but the evidence is very weak and further research is required. [50] THC preparations, gabapentin, oxytocin, and N-acetylcysteine also require more research to determine if they are effective as the evidence base is weak. [50]

Heavy cannabis use has been associated with impaired cognitive functioning; however, its specific details are difficult to elucidate due to the potential use of additional substances of users, and lack of longitudinal studies. [73]

See also

Related Research Articles

<span class="mw-page-title-main">Alcoholism</span> Problematic excessive alcohol consumption

Alcoholism is the continued drinking of alcohol despite it causing problems. Some definitions require evidence of dependence and withdrawal. Problematic use of alcohol has been mentioned in the earliest historical records. The World Health Organization (WHO) estimated there were 283 million people with alcohol use disorders worldwide as of 2016. The term alcoholism was first coined in 1852, but alcoholism and alcoholic are sometimes considered stigmatizing and to discourage seeking treatment, so diagnostic terms such as alcohol use disorder or alcohol dependence are often used instead in a clinical context.

<span class="mw-page-title-main">Substance abuse</span> Harmful use of drugs

Substance abuse, also known as drug abuse, is the use of a drug in amounts or by methods that are harmful to the individual or others. It is a form of substance-related disorder. Differing definitions of drug abuse are used in public health, medical, and criminal justice contexts. In some cases, criminal or anti-social behavior occurs when the person is under the influence of a drug, and long-term personality changes in individuals may also occur. In addition to possible physical, social, and psychological harm, the use of some drugs may also lead to criminal penalties, although these vary widely depending on the local jurisdiction.

<span class="mw-page-title-main">Effects of cannabis</span>

The effects of cannabis are caused by chemical compounds in the cannabis plant, including 113 different cannabinoids such as tetrahydrocannabinol (THC) and 120 terpenes, which allow its drug to have various psychological and physiological effects on the human body. Different plants of the genus Cannabis contain different and often unpredictable concentrations of THC and other cannabinoids and hundreds of other molecules that have a pharmacological effect, so the final net effect cannot reliably be foreseen.

<span class="mw-page-title-main">Medical cannabis</span> Marijuana used medicinally

Medical cannabis, medicinal cannabis or medical marijuana (MMJ), is cannabis and cannabinoids that are prescribed by physicians for their patients. The use of cannabis as medicine has not been rigorously tested due to production and governmental restrictions, resulting in limited clinical research to define the safety and efficacy of using cannabis to treat diseases.

Drug withdrawal, drug withdrawal syndrome, or substance withdrawal syndrome, is the group of symptoms that occur upon the abrupt discontinuation or decrease in the intake of pharmaceutical or recreational drugs.

<span class="mw-page-title-main">Opioid use disorder</span> Medical condition

Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical and/or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder.

The gateway drug effect is a comprehensive catchphrase for the often observed effect that the use of a psychoactive substance is coupled to an increased probability of the use of further substances. Possible reasons for the connection include environmental influence, impulsive people seeking both soft and hard drugs, alterations in the brain due to earlier substance exposure, as well as similar attitudes of people who use different substances, and therefore experience a "common liability to addiction". In 2020, the National Institute on Drug Abuse released a research report which supported allegations that marijuana is a "gateway" to more dangerous substance use; one of the peer-reviewed papers cited in the report claims that while "some studies have found that use of legal drugs or cannabis are not a requirement for the progression to other illicit drugs [...] most studies have supported the "gateway sequence"." However, a 2018 literature review conducted by the National Institute of Justice, which analyzed 23 peer-reviewed research studies, concluded "that existing statistical research and analysis relevant to the "gateway" hypothesis has produced mixed results", and that "no causal link between cannabis use and the use of other illicit drugs can be claimed at this time."

<span class="mw-page-title-main">Cannabis (drug)</span> Psychoactive drug from the cannabis plant

Cannabis, also known as marijuana or weed, among other names, is a non-chemically uniform drug from the cannabis plant. Native to Central or South Asia, the cannabis plant has been used as a drug for both recreational and entheogenic purposes and in various traditional medicines for centuries. Tetrahydrocannabinol (THC) is the main psychoactive component of cannabis, which is one of the 483 known compounds in the plant, including at least 65 other cannabinoids, such as cannabidiol (CBD). Cannabis can be used by smoking, vaporizing, within food, or as an extract.

Substance dependence, also known as drug dependence, is a biopsychological situation whereby an individual's functionality is dependent on the necessitated re-consumption of a psychoactive substance because of an adaptive state that has developed within the individual from psychoactive substance consumption that results in the experience of withdrawal and that necessitates the re-consumption of the drug. A drug addiction, a distinct concept from substance dependence, is defined as compulsive, out-of-control drug use, despite negative consequences. An addictive drug is a drug which is both rewarding and reinforcing. ΔFosB, a gene transcription factor, is now known to be a critical component and common factor in the development of virtually all forms of behavioral and drug addictions, but not dependence.

An addictive behavior is a behavior, or a stimulus related to a behavior, that is both rewarding and reinforcing, and is associated with the development of an addiction. There are two main forms of addiction: substance use disorders and behavioral addiction. The parallels and distinctions between behavioral addictions and other compulsive behavior disorders like bulimia nervosa and obsessive-compulsive disorder (OCD) are still being researched by behavioral scientists.

Dual diagnosis is the condition of having a mental illness and a comorbid substance use disorder. There is considerable debate surrounding the appropriateness of using a single category for a heterogeneous group of individuals with complex needs and a varied range of problems. The concept can be used broadly, for example depression and alcohol use disorder, or it can be restricted to specify severe mental illness and substance use disorder, or a person who has a milder mental illness and a drug dependency, such as panic disorder or generalized anxiety disorder and is dependent on opioids. Diagnosing a primary psychiatric illness in people who use substances is challenging as substance use disorder itself often induces psychiatric symptoms, thus making it necessary to differentiate between substance induced and pre-existing mental illness.

<span class="mw-page-title-main">Nicotine dependence</span> Chronic disease

Nicotine dependence is a state of dependence upon nicotine. Nicotine dependence is a chronic, relapsing disease defined as a compulsive craving to use the drug, despite social consequences, loss of control over drug intake, and emergence of withdrawal symptoms. Tolerance is another component of drug dependence. Nicotine dependence develops over time as a person continues to use nicotine. The most commonly used tobacco product is cigarettes, but all forms of tobacco use and e-cigarette use can cause dependence. Nicotine dependence is a serious public health problem because it leads to continued tobacco use, which is one of the leading preventable causes of death worldwide, causing more than 8 million deaths per year.

Cocaine dependence is a neurological disorder that is characterized by withdrawal symptoms upon cessation from cocaine use. It also often coincides with cocaine addiction which is a biopsychosocial disorder characterized by persistent use of cocaine and/or crack despite substantial harm and adverse consequences. The Diagnostic and Statistical Manual of Mental Disorders, classifies problematic cocaine use as a stimulant use disorder. The International Classification of Diseases, includes "Cocaine dependence" as a classification (diagnosis) under "Disorders due to use of cocaine".

<span class="mw-page-title-main">Polysubstance dependence</span> A type of substance use disorder

Polysubstance dependence refers to a type of substance use disorder in which an individual uses at least three different classes of substances indiscriminately and does not have a favorite substance that qualifies for dependence on its own. Although any combination of three substances can be used, studies have shown that alcohol is commonly used with another substance. One study on polysubstance use categorized participants who used multiple substances according to their substance of preference. The results of a longitudinal study on substance use led the researchers to observe that excessively using or relying on one substance increased the probability of excessively using or relying on another substance.

<span class="mw-page-title-main">Long-term effects of cannabis</span>

The long-term effects of cannabis have been the subject of ongoing debate. Given that the use of cannabis is illegal in most countries, clinical research presents a challenge and there is limited evidence from which to draw conclusions. In 2017, the U.S. National Academies of Sciences, Engineering, and Medicine issued a report summarizing much of the published literature on health effects of cannabis, into categories regarded as conclusive, substantial, moderate, limited and of no or insufficient evidence to support an association with a particular outcome.

<span class="mw-page-title-main">Substance use disorder</span> Continual use of drugs (including alcohol) despite detrimental consequences

Substance use disorder (SUD) is the persistent use of drugs despite the substantial harm and adverse consequences to one's own self and others, as a result of their use. In perspective, the effects of the wrong use of substances that are capable of causing harm to the user or others, have been extensively described in different studies using a variety of terms such as substance use problems, problematic drugs or alcohol use, and substance use disorder.The National Institute of Mental Health (NIMH) states that "Substance use disorder (SUD) is a treatable mental disorder that affects a person's brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe, with addiction being the most severe form of SUD".Substance use disorders (SUD) are considered to be a serious mental illness that fluctuates with the age that symptoms first start appearing in an individual, the time during which it exists and the type of substance that is used. It is not uncommon for those who have SUD to also have other mental health disorders. Substance use disorders are characterized by an array of mental/emotional, physical, and behavioral problems such as chronic guilt; an inability to reduce or stop consuming the substance(s) despite repeated attempts; operating vehicles while intoxicated; and physiological withdrawal symptoms. Drug classes that are commonly involved in SUD include: alcohol (alcoholism); cannabis; opioids; stimulants such as nicotine (including tobacco), cocaine and amphetamines; benzodiazepines; barbiturates; and other substances.

<span class="mw-page-title-main">Addiction</span> Disorder resulting in compulsive behaviours

Addiction is a neuropsychological disorder characterized by a persistent and intense urge to use a drug or engage in a behavior that produces natural reward, despite substantial harm and other negative consequences. Repetitive drug use often alters brain function in ways that perpetuate craving, and weakens self-control. This phenomenon – drugs reshaping brain function – has led to an understanding of addiction as a brain disorder with a complex variety of psychosocial as well as neurobiological factors that are implicated in addiction's development.

Discrimination against people with substance use disorders is a form of discrimination against people with this disease. In the United States, people with substance use disorders are often blamed for their disease, which is often seen as a moral failing, due to a lack of public understanding about substance use disorders being diseases of the brain with 40-60% heritability. People with substance use disorders are likely to be stigmatized, whether in society or healthcare.

Trauma contributed to promoting the use and potential abuse of cannabis. Conversely, cannabis use has been associated with the intensity of trauma and PTSD symptoms. While evidence of efficacious use of cannabis is growing in novelty, it is not currently recommended.

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

References

  1. ↑ Jacobus, Joanna; Goldenberg, Diane; Wierenga, Christina E.; Tolentino, Neil J.; Liu, Thomas T.; Tapert, Susan F. (1 August 2012). "Altered cerebral blood flow and neurocognitive correlates in adolescent cannabis users". Psychopharmacology. 222 (4): 675–684. doi:10.1007/s00213-012-2674-4. ISSN   1432-2072. PMC   3510003 . PMID   22395430.
  2. ↑ National Institute on Drug Abuse (2014), The Science of Drug Abuse and Addiction: The Basics, archived from the original on 1 April 2022, retrieved 17 March 2016
  3. 1 2 Gordon AJ, Conley JW, Gordon JM (December 2013). "Medical consequences of marijuana use: a review of current literature". Current Psychiatry Reports (Review). 15 (12): 419. doi:10.1007/s11920-013-0419-7. PMID   24234874. S2CID   29063282.
  4. ↑ Smith, Dana (10 April 2023). "How Do You Know if You're Addicted to Weed?". The New York Times . Retrieved 24 June 2024.
  5. ↑ MacDonald, Kai (1 April 2016). "Why Not Pot?: A Review of the Brain-based Risks of Cannabis". Innovations in Clinical Neuroscience . 13 (3–4): 13–22. PMC   4911936 . PMID   27354924.
  6. 1 2 3 4 5 6 7 Danovitch I, Gorelick DA (June 2012). "State of the art treatments for cannabis dependence". The Psychiatric Clinics of North America (Review). 35 (2): 309–26. doi:10.1016/j.psc.2012.03.003. PMC   3371269 . PMID   22640758.
  7. ↑ Dervaux A, Laqueille X (December 2012). "[Cannabis: Use and dependence]". Presse Médicale (in French). 41 (12 Pt 1): 1233–40. doi:10.1016/j.lpm.2012.07.016. PMID   23040955.
  8. ↑ E.B., Robertson. "Information on Cannabis Addiction". National Institute on Drug Abuse. Archived from the original on 7 May 2018. Retrieved 7 May 2018.
  9. 1 2 Clinical Textbook of Addictive Disorders, Marijuana, David McDowell, page 169, Published by Guilford Press, 2005 ISBN   1-59385-174-X.
  10. ↑ Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, et al. (June 2012). "Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers". Molecular Psychiatry. 17 (6): 642–9. doi:10.1038/mp.2011.82. PMC   3223558 . PMID   21747398.
  11. ↑ Madras BK (August 2014). "Dopamine challenge reveals neuroadaptive changes in marijuana abusers". Proceedings of the National Academy of Sciences of the United States of America. 111 (33): 11915–6. Bibcode:2014PNAS..11111915M. doi: 10.1073/pnas.1412314111 . PMC   4143049 . PMID   25114244.
  12. 1 2 González S, Cebeira M, Fernández-Ruiz J (June 2005). "Cannabinoid tolerance and dependence: a review of studies in laboratory animals". Pharmacology, Biochemistry, and Behavior. 81 (2): 300–18. doi:10.1016/j.pbb.2005.01.028. PMID   15919107. S2CID   23328509.
  13. ↑ Maldonado R, Berrendero F, Ozaita A, Robledo P (May 2011). "Neurochemical basis of cannabis addiction". Neuroscience. 181: 1–17. doi:10.1016/j.neuroscience.2011.02.035. PMID   21334423. S2CID   6660057.
  14. ↑ "Marijuana use disorder is common and often untreated". National Institutes of Health (NIH). 4 March 2016. Retrieved 3 April 2019.
  15. ↑ Wilkie G, Sakr B, Rizack T (May 2016). "Medical Marijuana Use in Oncology: A Review". JAMA Oncology. 2 (5): 670–675. doi: 10.1001/jamaoncol.2016.0155 . PMID   26986677.
  16. 1 2 3 Budney AJ, Roffman R, Stephens RS, Walker D (December 2007). "Marijuana dependence and its treatment". Addiction Science & Clinical Practice. 4 (1): 4–16. doi:10.1151/ascp07414. PMC   2797098 . PMID   18292704.
  17. 1 2 Borgelt LM, Franson KL, Nussbaum AM, Wang GS (February 2013). "The pharmacologic and clinical effects of medical cannabis". Pharmacotherapy (Review). 33 (2): 195–209. doi: 10.1002/phar.1187 . PMID   23386598. S2CID   8503107.
  18. ↑ Bahji, Anees; Stephenson, Callum; Tyo, Richard; Hawken, Emily R.; Seitz, Dallas P. (9 April 2020). "Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids". JAMA Network Open. 3 (4): e202370. doi: 10.1001/jamanetworkopen.2020.2370 . PMC   7146100 . PMID   32271390.
  19. ↑ Livne O, Shmulewitz D, Lev-Ran S, Hasin DS (February 2019). "DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults". Drug and Alcohol Dependence. 195: 170–177. doi:10.1016/j.drugalcdep.2018.09.005. PMC   6359953 . PMID   30361043.
  20. ↑ Allsop, David (2011). "The Cannabis Withdrawal Scale development: Patterns and predictors of cannabis withdrawal and distress". Drug and Alcohol Dependence. 119 (1–2): 123–129. doi:10.1016/j.drugalcdep.2011.06.003. PMID   21724338 . Retrieved 12 March 2024.
  21. ↑ Cougle, Jesse R.; Hakes, Jahn K.; Macatee, Richard J.; Zvolensky, Michael J.; Chavarria, Jesus (27 April 2016). "Probability and Correlates of Dependence Among Regular Users of Alcohol, Nicotine, Cannabis, and Cocaine: Concurrent and Prospective Analyses of the National Epidemiologic Survey on Alcohol and Related Conditions". The Journal of Clinical Psychiatry. 77 (4): e444–e450. doi:10.4088/JCP.14m09469. PMID   27137428.
  22. ↑ Connor, Jason P.; Stjepanović, Daniel; Le Foll, Bernard; Hoch, Eva; Budney, Alan J.; Hall, Wayne D. (25 February 2021). "Cannabis use and cannabis use disorder". Nature Reviews Disease Primers. 7 (1): 3. doi:10.1038/s41572-021-00247-4. ISSN   2056-676X. PMC   8655458 . PMID   33627670.
  23. ↑ Coffey C, Carlin JB, Lynskey M, Li N, Patton GC (April 2003). "Adolescent precursors of cannabis dependence: findings from the Victorian Adolescent Health Cohort Study". The British Journal of Psychiatry. 182 (4): 330–6. doi: 10.1192/bjp.182.4.330 . PMID   12668409.
  24. ↑ "DrugFacts: Marijuana". National Institute on Drug Abuse. Retrieved 20 July 2015.
  25. 1 2 3 Gorelick, David A. (14 December 2023). "Cannabis-Related Disorders and Toxic Effects". New England Journal of Medicine. 389 (24): 2267–2275. doi:10.1056/NEJMra2212152. PMID   38091532.
  26. 1 2 Copeland J, Gerber S, Swift W (December 2004). Evidence-based answers to cannabis questions a review of the literature. National Drug and Alcohol Research Centre University of New South Wales, A report prepared for the Australian National Council on Drugs.
  27. ↑ McLaren, J, Mattick, R P., Cannabis in Australia Use, supply, harms, and responses Monograph series No. 57 Report prepared for: Drug Strategy Branch Australian Government Department of Health and Ageing. National Drug and Alcohol Research Centre University of New South Wales, Australia.
  28. 1 2 Volkow, Nora D.; Swanson, James M.; Evins, A. Eden; DeLisi, Lynn E.; Meier, Madeline H.; Gonzalez, Raul; Bloomfield, Michael A. P.; Curran, H. Valerie; Baler, Ruben (1 March 2016). "Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review" (PDF). JAMA Psychiatry. 73 (3): 292–7. doi:10.1001/jamapsychiatry.2015.3278. ISSN   2168-622X. PMID   26842658.
  29. ↑ Levine, Amir; Clemenza, Kelly; Rynn, Moira; Lieberman, Jeffrey (1 March 2017). "Evidence for the Risks and Consequences of Adolescent Cannabis Exposure". Journal of the American Academy of Child & Adolescent Psychiatry. 56 (3): 214–225. doi:10.1016/j.jaac.2016.12.014. ISSN   0890-8567. PMID   28219487.
  30. ↑ National Academies of Sciences, Engineering, and Medicine (U.S.). Committee on the Health Effects of Marijuana: an Evidence Review and Research Agenda. (2017). The health effects of cannabis and cannabinoids : the current state of evidence and recommendations for research. The National Academies Press. ISBN   978-0-309-45304-2. OCLC   1021254335.{{cite book}}: CS1 maint: multiple names: authors list (link)
  31. ↑ Montoya, Ivan D.; Weiss, Susan R. B. (2018). Cannabis use disorders (1 ed.). New York, NY: Springer Berlin Heidelberg. ISBN   978-3-319-90364-4. OCLC   1029794724.
  32. 1 2 SANDERS, Bill (2005). Youth Crime and Youth Culture in the Inner City. Taylor and Francis Group.
  33. ↑ LEMIRE, L. (2014). Enquête québécoise sur la santé des jeunes du secondaire 2010-2011. Santé publique. Récupéré de http://www.cisss-lanaudiere.gouv.qc.ca/fileadmin/internet/cisss_lanaudiere/Documentation/Sante_publique/Themes/Sante_mentale_et_psychosociale/EQSJS-Envir_social-Amis-VF.pdf
  34. 1 2 3 LEOS-TORO, C., FONG, G. T., MEYER, S. B. et HAMMOND, D. (2020). Cannabis health knowledge and risk perceptions among Canadian youth and young adults. Harm Reduction Journal. London. Vol. 17. (p.1-13).
  35. ↑ LEOS-TORO, C., FONG, G. T., MEYER, S. B. et HAMMOND, D. (2020). Cannabis health knowledge and risk perceptions among Canadian youth and young adults. Harm Reduction Journal. London. Vol. 17. (p.1-13)
  36. ↑ "Committee Opinion No. 722: Marijuana Use During Pregnancy and Lactation". Obstetrics & Gynecology. 130 (4): e205–e209. October 2017. doi:10.1097/AOG.0000000000002354.
  37. 1 2 3 Gunn, J K L; Rosales, C B; Center, K E; Nuñez, A; Gibson, S J; Christ, C; Ehiri, J E (2016). "Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis". BMJ Open. 6 (4): e009986. doi:10.1136/bmjopen-2015-009986. ISSN   2044-6055. PMC   4823436 . PMID   27048634.
  38. ↑ Metz, Torri D.; Stickrath, Elaine H. (December 2015). "Marijuana use in pregnancy and lactation: a review of the evidence". American Journal of Obstetrics and Gynecology. 213 (6): 761–778. doi:10.1016/j.ajog.2015.05.025. ISSN   0002-9378. PMID   25986032.
  39. ↑ Brown, R.A.; Dakkak, H.; Seabrook, J.A. (21 December 2018). "Is Breast Best? Examining the effects of alcohol and cannabis use during lactation". Journal of Neonatal-Perinatal Medicine. 11 (4): 345–356. doi:10.3233/npm-17125. ISSN   1934-5798. PMID   29843260. S2CID   44153511.
  40. ↑ Seabrook, J.A.; Biden, C.; Campbell, E. (2017). "Does the risk of exposure to marijuana outweigh the benefits of breastfeeding? A systematic review". Canadian Journal of Midwifery Research and Practice. 16 (2): 8–16.
  41. ↑ "Proposed Revision | APA DSM-5". Dsm5.org. Retrieved 20 April 2011.
  42. ↑ "DSM-5 Now Categorizes Substance Use Disorder in a Single Continuum". American Psychiatric Association. 17 May 2013. Archived from the original on 7 February 2015. Retrieved 12 December 2013.
  43. ↑ Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, et al. (August 2013). "DSM-5 criteria for substance use disorders: recommendations and rationale". The American Journal of Psychiatry. 170 (8): 834–51. doi:10.1176/appi.ajp.2013.12060782. PMC   3767415 . PMID   23903334.
  44. ↑ "ICD-11 – Mortality and Morbidity Statistics". icd.who.int. Retrieved 17 November 2019.
  45. ↑ "ICD-10 Version:2016". icd.who.int. Retrieved 17 November 2019.
  46. ↑ Murrie, Benjamin; Lappin, Julia; Large, Matthew; Sara, Grant (16 October 2019). "Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis". Schizophrenia Bulletin. 46 (3): 505–516. doi: 10.1093/schbul/sbz102 . PMC   7147575 . PMID   31618428.
  47. ↑ Casajuana, Cristina; López-Pelayo, Hugo; Balcells, María Mercedes; Miquel, Laia; Colom, Joan; Gual, Antoni (2016). "Definitions of Risky and Problematic Cannabis Use: A Systematic Review". Substance Use & Misuse. 51 (13): 1760–1770. doi:10.1080/10826084.2016.1197266. ISSN   1532-2491. PMID   27556867. S2CID   32299878.
  48. 1 2 3 4 López-Pelayo, H.; Batalla, A.; Balcells, M. M.; Colom, J.; Gual, A. (2015). "Assessment of cannabis use disorders: a systematic review of screening and diagnostic instruments". Psychological Medicine. 45 (6): 1121–1133. doi:10.1017/S0033291714002463. ISSN   1469-8978. PMID   25366671. S2CID   206254638.
  49. ↑ Substance Abuse and Mental Health Services Administration, Office of Applied Studies. (2003). Emergency department trends from the drug abuse warning network, final estimates 1995–2002, DAWN Series: D-24, DHHS Publication No. (SMA) 03-3780.
  50. 1 2 3 4 Nielsen S, Gowing L, Sabioni P, Le Foll B (January 2019). "Pharmacotherapies for cannabis dependence". The Cochrane Database of Systematic Reviews. 1 (3): CD008940. doi:10.1002/14651858.CD008940.pub3. PMC   6360924 . PMID   30687936.
  51. ↑ Degenhardt L, Hall W, Lynskey M (2000). Cannabis use and mental health among Australian adults: Findings from the National Survey of Mental Health and Well-being, NDARC Technical Report No. 98. Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
  52. ↑ Copeland J, Swift W (April 2009). "Cannabis use disorder: epidemiology and management". International Review of Psychiatry (Review). 21 (2): 96–103. doi:10.1080/09540260902782745. PMID   19367503. S2CID   10881676.
  53. ↑ EMCDDA (2007). Annual report 2007: The state of the drugs problem in Europe. Luxembourg: Office for Official Publications of the European Communities.
  54. ↑ Gates, Peter J.; Sabioni, Pamela; Copeland, Jan; Le Foll, Bernard; Gowing, Linda (5 May 2016). "Psychosocial interventions for cannabis use disorder". The Cochrane Database of Systematic Reviews. 2016 (5): CD005336. doi:10.1002/14651858.CD005336.pub4. ISSN   1469-493X. PMC   4914383 . PMID   27149547.
  55. ↑ Sussman, Steve (1010). "A Review of Alcoholics Anonymous/Narcotics Anonymous Programs for Teens". Evaluation & the Health Professions. 33 (1): 26–55. doi:10.1177/0163278709356186. PMC   4181564 . PMID   20164105.
  56. ↑ "With Support From Collaborative, Primary Care Practices Identify and Address Behavioral Health Issues, Reducing Binge Drinking, Marijuana Use, and Depression Symptoms". Agency for Healthcare Research and Quality. 8 May 2013. Retrieved 10 May 2013.
  57. ↑ Zehra A, Burns J, Liu CK, Manza P, Wiers CE, Volkow ND, Wang GJ (December 2018). "Cannabis Addiction and the Brain: a Review". Journal of Neuroimmune Pharmacology. 13 (4): 438–452. doi:10.1007/s11481-018-9782-9. PMC   6223748 . PMID   29556883.
  58. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Brezing CA, Levin FR (January 2018). "The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal". Neuropsychopharmacology. 43 (1): 173–194. doi:10.1038/npp.2017.212. PMC   5719115 . PMID   28875989.
  59. ↑ Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J (2018). "Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review" (PDF). Psychotherapy and Psychosomatics. 87 (4): 195–203. doi: 10.1159/000491524 . PMID   30016772. S2CID   51677365.
  60. ↑ "Generalised anxiety disorder – NICE Pathways". pathways.nice.org.uk. NICE. Archived from the original on 29 March 2019. Retrieved 13 April 2019.
  61. ↑ Sabioni, Pamela; Le Foll, Bernard (2018). "Psychosocial and pharmacological interventions for the treatment of cannabis use disorder". F1000Research. 7: 173. doi: 10.12688/f1000research.11191.1 . ISSN   2046-1402. PMC   5811668 . PMID   29497498.
  62. ↑ Treloar C, Holt M (2006). "Deficit models and divergent philosophies: Service providers' perspectives on barriers and incentives to drug treatment". Drugs: Education Prevention and Policy. 13 (4): 367–382. doi:10.1080/09687630600761444. S2CID   73095850.
  63. ↑ Treloar C, Abelson J, Cao W, Brener L, Kippax S, Schultz L, Schultz M, Bath N (2004). Barriers and incentives to treatment for illicit drug users. Monograph Series 53. Canberra: Department of Health and Ageing, National Drug Strategy.
  64. ↑ Gates P, Taplin S, Copeland J, Swift W, Martin G (2008). "Barriers and Facilitators to Cannabis Treatment". Drug and Alcohol Review. 31 (3). National Cannabis Prevention and Information Centre, University of New South Wales, Sydney: 311–9. doi:10.1111/j.1465-3362.2011.00313.x. PMID   21521384.
  65. ↑ "WDR 2022_Booklet 2". United Nations : Office on Drugs and Crime. Retrieved 7 November 2022.
  66. ↑ "6 facts about marijuana". 10 April 2024.
  67. ↑ Marshall K, Gowing L, Ali R, Le Foll B (17 December 2014). "Pharmacotherapies for cannabis dependence". The Cochrane Database of Systematic Reviews. 12 (12): CD008940. doi:10.1002/14651858.CD008940.pub2. PMC   4297244 . PMID   25515775.
  68. ↑ "Treatment Episode Data Set (TEDS)2001 – 2011. National Admissions to Substance Abuse Treatment Services" (PDF). samhsa.gov. Substance Abuse and Mental Health Services Administration. Archived from the original (PDF) on 1 August 2017. Retrieved 17 April 2015.
  69. ↑ "Drug Info". Australian Drug Foundation. Archived from the original on 25 April 2011.
  70. ↑ "Statistical Bulletin 2018 — prevalence of drug use | www.emcdda.europa.eu". emcdda.europa.eu. Retrieved 5 February 2019.
  71. ↑ "Summary | www.espad.org". espad.org. Retrieved 5 February 2019.
  72. ↑ Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. (GBD 2016 Alcohol and Drug Use Collaborators) (December 2018). "The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016". The Lancet. Psychiatry. 5 (12): 987–1012. doi:10.1016/S2215-0366(18)30337-7. PMC   6251968 . PMID   30392731.
  73. ↑ Scott, JC; Slomiak, ST; Jones, JD; Rosen, AFG; Moore, TM; Gur, RC (1 June 2018). "Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults: A Systematic Review and Meta-analysis". JAMA Psychiatry. 75 (6): 585–595. doi:10.1001/jamapsychiatry.2018.0335. PMC   6137521 . PMID   29710074.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.